The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).
 
Meng XU WELLIVER
No Relationships to Disclose
 
Brian Andrew Van Tine
Consulting or Advisory Role - Caris Life Sciences; CytRx Corporation; EMD Serono; Johnson & Johnson; Lilly/ImClone; Novartis; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; Johnson & Johnson; Lilly; Novartis
Research Funding - Merck; Pfizer
Expert Testimony - Me1 Patient
 
Peter Houghton
No Relationships to Disclose
 
Michelle A. Rudek
Employment - Novavax (I)
Stock and Other Ownership Interests - Amplimmune (I); Novavax (I)
Research Funding - Celgene (Inst); RenovoRx (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Expert Medical Events
 
Raphael E. Pollock
No Relationships to Disclose
 
John Michael Kane
No Relationships to Disclose
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer
Honoraria - Array BioPharma; Bayer; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Consulting or Advisory Role - Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Gencirq; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Daiichi Sankyo; Iovance Biotherapeutics; PTC Therapeutics; PureTech
 
Peixin Zhang
No Relationships to Disclose
 
David G. Kirsch
Stock and Other Ownership Interests - Lumicell; X-RAD Therapeutics
Consulting or Advisory Role - Lumicell
Research Funding - Bristol-Myers Squibb; Lilly; Merck; X-RAD Therapeutics
Patents, Royalties, Other Intellectual Property - Co-founder and own stock in XRAD Therapeutics, which is commercializing small molecular radiosensitizers; Patent on an imaging device licensed to Lumicell; Royalty on an imaging agent being commercialized by Lumicell
Other Relationship - SARC: Sarcoma Alliance for Research though Collaboration
 
Paul Wakely
No Relationships to Disclose
 
Steve B. Jiang
No Relationships to Disclose
 
Shahanawaz Jiwani
No Relationships to Disclose
 
Alan D. Rogers
No Relationships to Disclose
 
Dian Wang
No Relationships to Disclose